CorMedix Inc
CRMD16.560USD
+2.950+21.68%
Cierre 06/23, 16:00（ET）Cotizaciones retrasadas 15 min
1.12BCap. mercado
PérdidaP/E TTM
Más Datos de CorMedix Inc Compañía
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Información de la empresa
Símbolo de cotizaciónCRMD
Nombre de la empresaCorMedix Inc
Fecha de salida a bolsaMar 25, 2010
Fundada en2006
Director ejecutivoMr. Joseph Todisco
Número de empleados64
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 25
Dirección300 Connell Drive
CiudadBERKELEY HEIGHTS
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal07922
Teléfono19085179500
Sitio Webhttps://cormedix.com/
Símbolo de cotizaciónCRMD
Fecha de salida a bolsaMar 25, 2010
Fundada en2006
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Desglose de ingresos
FY2024
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
43.47M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
13.86%
Investment Advisor/Hedge Fund
13.60%
Hedge Fund
5.69%
Research Firm
1.60%
Sovereign Wealth Fund
1.39%
Individual Investor
1.19%
Pension Fund
0.45%
Bank and Trust
0.30%
Venture Capital
0.06%
Other
61.88%
Participación institucional
Actualizado: lun., 24 de feb
Actualizado: lun., 24 de feb
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
262
29.51M
43.73%
+3.54M
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
2022Q4
191
11.93M
28.90%
-1.83M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
4.20M
6.44%
+868.26K
+26.06%
Dec 31, 2024
The Vanguard Group, Inc.
3.38M
5.18%
+309.51K
+10.09%
Dec 31, 2024
Elliott Management Corporation
2.87M
4.4%
+1.32M
+85.14%
Dec 31, 2024
State Street Global Advisors (US)
1.45M
2.23%
+227.39K
+18.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.39M
2.14%
+108.36K
+8.44%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
940.59K
1.44%
+940.59K
--
Dec 31, 2024
UBS Financial Services, Inc.
379.87K
0.58%
+340.35K
+861.30%
Dec 31, 2024
Morgan Stanley & Co. LLC
283.12K
0.43%
+50.06K
+21.48%
Dec 31, 2024
Northern Trust Investments, Inc.
510.89K
0.78%
+100.11K
+24.37%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Active Factor Small Cap ETF
0.17%
iShares Micro-Cap ETF
0.13%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.49%
First Trust Active Factor Small Cap ETF
Proporción0.17%
iShares Micro-Cap ETF
Proporción0.13%
Vanguard US Momentum Factor ETF
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.08%
iShares Biotechnology ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.06%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
